Dr Rebekah Puls

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, vol. 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5

Berthon-Jones N; Courtney-Vega K; Donaldson A; Haskelberg H; Emery S; Puls R, 2015, 'Assessing site performance in the Altair study, a multinational clinical trial', Trials, vol. 16, http://dx.doi.org/10.1186/s13063-015-0653-x

Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avinghsanon A; Chetchotisakd P; Khoo S; Cooper DA; Emery S; Puls R, 2015, 'Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: A randomized controlled trial', Clinical Infectious Diseases, vol. 60, pp. 1026 - 1032, http://dx.doi.org/10.1093/cid/ciu976

Winston A; Puls R; Kerr SJ; Duncombe C; Li P; Gill JM; Ramautarsing R; Taylor-Robinson SD; Emery S; Cooper DA; Belloso W; Gazzard B; Hung CC; Jessen H; Kamrulazaman A; Li L; Losso M; Sierra-Madero J; Mallon P; Mason B; Molina JM; Petoumenos K; Phanuphak P; Pollack S; Rooney J; Walmsley S; Wolff M, 2015, 'Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0118608

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Emery S; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Losso M; Nwizu C; Phanuphak P; Ripin D; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Boyd M; Carey D; Clarke A; Courtney-Vega K; Dazo C; Delfino M; Donaldson A; Espinosa N; Johannesen T; Kaew-On P; Lin E; Moricz A; Taylor J; Phanupak P; Puls RL; Pussadee K; Sutheerasak P; Tomkins L; Ubolyam S; Shah Bin Raja Azwa RI; Bissio E; Calanni L; Casiro A; Chetchotisakd P; Contarelli J; Doong N; Elliott J; Gazzard B; Kelly M; Del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Pett S; Rockstroh J; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Crabtree-Ramiraz B; Winston E; Dunn D; Dolan M, 2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, vol. 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X

Amin J; Law MG; Puls R; Kelleher A; Cooper DA; Emery S, 2014, 'Comparison of central and local HIV-1 RNA quantification from two international clinical trials', AIDS, vol. 28, pp. 2480 - 2483, http://dx.doi.org/10.1097/QAD.0000000000000461

Winston A; Puls R, 2014, 'Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial.', J Int AIDS Soc, vol. 17, pp. 19541, http://dx.doi.org/10.7448/IAS.17.4.19541

Amara AB; Else LJ; Tjia J; Olagunju A; Puls R; Khoo S; Back DJ, 2014, 'A Validated Method for Quantification of Efavirenz in Dried Blood Spots (DBS) using HPLC-MS/MS', Therapeutic Drug Monitoring, vol. 2014 Aug 26. [Epub ahead of print], pp. 1 - 27, http://dx.doi.org/10.1097/FTD.0000000000000127

Pussadee K; Phanuphak P; Ruengprasertkit C; Kaewon P; Butterworth O; Pinklow P; Puls R, 2013, 'Experience in setting up a Thai Coordinating Centre', Thai AIDS Journal, vol. 25, pp. 51 - 57

Else L; Jackson A; Puls R; Hill A; Fahey P; Lin E; Amara A; Siccardi M; Watson V; Tjia JF; Emery S; Khoo SK; Back D; Boffito M, 2012, 'Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: Results of the ENCORE 2 study', Antimicrobial Agents and Chemotherapy, vol. 56, pp. 1427 - 1433, http://dx.doi.org/10.1128/AAC.05599-11

Winston A; Duncombe CJ; Li PCK; Gill JM; Kerr SJ; Puls R; Taylor-Robinson SD; Emery S; Cooper DA, 2012, 'Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.', Neuroradiology, vol. 54, pp. 1331 - 1339, http://dx.doi.org/10.1007/s00234-012-1061-5

Winston A; Puls R; Kerr SJ; Duncombe CJ; Li PCK; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA, 2012, 'Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: A randomized, controlled study', HIV Medicine, vol. 13, pp. 245 - 251, http://dx.doi.org/10.1111/j.1468-1293.2011.00962.x

Jackson A; Hill A; Puls R; Else L; Amin J; Back D; Lin E; Khoo S; Emery S; Morley R; Gazzard B; Boffito M, 2011, 'Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers', Journal of Antimicrobial Chemotherapy, vol. 66, pp. 635 - 640, http://dx.doi.org/10.1093/jac/dkq468

Puls R; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe CJ; Belloso WH; Molina J; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S, 2010, 'Efavirenz versus boosted atazanavir or zidovudine and abacavir in antirectroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study', Clinical Infectious Diseases, vol. Oct 1; 51, pp. 855 - 864, http://dx.doi.org/10.1086/656363

Hemachandra A; Puls R; Sirivichayakul S; Kerr SJ; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher AD; Ruxrungtham K, 2010, 'An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection', Human Vaccines, vol. 6, pp. 835 - 840, http://dx.doi.org/10.4161/hv.6.10.12635

Winston A; Duncombe C; Li P; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA, 2010, 'Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study', Clinical Infectious Diseases, vol. 50, pp. 920 - 929, http://dx.doi.org/10.1086/650743

Puls R; Brown D; Fahey P, 2010, 'Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study', Antiviral Therapy, vol. 15, pp. A28 - A29

Jackson AGA; Hill A; Else LJ; Back DJ; Morley R; Puls R; Amin J; Lin E; Boffito M, 2010, 'Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers', Journal of the International AIDS Society, vol. 13, pp. P180 - P180, http://dx.doi.org/10.1186/1758-2652-13-s4-p180

Hemachandra A; Puls RL; Kerr SJ; Saengthong N; Pussadee K; Emery S; Phanuphak P; Ruxrungtham K, 2009, 'P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand', Retrovirology, vol. 6, http://dx.doi.org/10.1186/1742-4690-6-S3-P202

Puls R; Srasuebkul P; Petoumenos K, 2009, 'Anthropometric and metabolic outcomes in a 48-week randomized, open-label study of three different combination antiretroviral regimens as initial therapy for HIV infection', Antiviral Therapy, vol. 14, pp. A8 - A9

Emery S; Kelleher AD; Workman C; Puls R; Bloch MT; Baker D; Hoy JF; Ip S; Nalliah K; Ward L; Law MG; Cooper DA, 2007, 'Influence of IFN gamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, vol. 3, pp. 260 - 267, http://dx.doi.org/10.4161/hv.4627

Law MG; Puls R; Cheng A; Cooper DA; Carr AD, 2006, 'Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults', Antiviral Therapy, vol. 11, pp. 179 - 186

Puls R; Emery S, 2006, 'Therapeutic vaccination against HIV: current progress and future possibilities', Clinical Science, vol. 110, pp. 59 - 71, http://dx.doi.org/10.1042/CS20050157

Kelleher AD; Puls R; Bebbington M; Boyle D; Kent S; Kippax SC; Purcell D; Thomson S; Wand HC; Cooper DA; Emery S; Ffrench RA, 2006, 'A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1', AIDS, vol. 20, pp. 294 - 297, http://dx.doi.org/10.1097/01.aids.0000199819.40079.e9

Emery S; Workman C; Puls R; Bloch M; Baker D; Bodsworth NJ; Anderson JA; Crowe SM; Hoy JF; Aichelburg A; Ward LA; Boyle D; Law MG; Kelleher AD; Cooper DA, 2005, 'Randomised, Placebo-Controlled, Phase 1/2a Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-y in HIV-1 Infected Subjects', Human Vaccines, vol. 1, pp. 232 - 238, http://dx.doi.org/10.4161/hv.1.6.2342

Jones ML; Young JM; Huang QR; Puls RL; Webber CA; Benson EM, 2003, 'Interleukin 12-augmented T cell proliferation of peripheral blood mononuclear cells from HIV-seropositive individuals is associated with interleukin 12 receptor β2 upregulation', AIDS Research and Human Retroviruses, vol. 19, pp. 283 - 292, http://dx.doi.org/10.1089/088922203764969483

Carr AD; Emery S; Law MG; Puls R; Lundgren JD; Powderly W, 2003, 'An objective case definition of lipodystrophy in HIV-infected adults: a case-control study', Lancet, vol. 361, pp. 726 - 735, http://dx.doi.org/10.1016/S0140-6736(03)12656-6

Puls R; Carr AD, 2003, 'Practical applications of the HIV lipodystrophy case definition', AIDS Reader, vol. 13, pp. 480 - 481

Puls RL; Minchin RF, 1999, 'Gene transfer and expression of a non-viral polycation-based vector in CD4⁺ cells', Gene Therapy, vol. 6, pp. 1774 - 1778, http://dx.doi.org/10.1038/sj.gt.3301022

Puls RL; Law M; Freund J; Gallagher D; Punyanitya M; Kalnins S; Carr A, 2002, 'The effect of centralized body composition data analysis on an objective case definition of HIV lipodystrophy', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CALIFORNIA, SAN DIEGO, pp. L53 - L53, presented at 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, CALIFORNIA, SAN DIEGO, 22 September 2002 - 25 September 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179501500089&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1